Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
32.3M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
35.1M
-
Shares change
-
+2.97M
-
Total reported value, excl. options
-
$766M
-
Value change
-
+$63.2M
-
Put/Call ratio
-
1.5
-
Number of buys
-
47
-
Number of sells
-
-35
-
Price
-
$21.80
Significant Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) as of Q4 2024
108 filings reported holding DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share as of Q4 2024.
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.1M shares
.
Largest 10 shareholders include FMR LLC (4.44M shares), Avidity Partners Management LP (2.87M shares), Fairmount Funds Management LLC (2.7M shares), Bain Capital Life Sciences Investors, LLC (2.69M shares), Octagon Capital Advisors LP (2.11M shares), RA CAPITAL MANAGEMENT, L.P. (1.87M shares), VR Adviser, LLC (1.74M shares), BlackRock, Inc. (1.65M shares), TCG Crossover Management, LLC (1.5M shares), and VANGUARD GROUP INC (1.27M shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.